Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With the United Kingdom's medical device regulatory framework undergoing significant evolution, how should non-UK manufacturers strategically evaluate the role and responsibilities of their UK Respons...
With the heightened responsibilities and legal liability assigned to the EU Authorized Representative (AR) under the Medical Device Regulation (MDR), how should a non-EU medical device manufacturer st...
When preparing a premarket submission for a connected medical device, how should manufacturers structure their cybersecurity documentation to align with FDA expectations? Beyond simply listing securit...
For manufacturers of moderate-risk, Class II in vitro diagnostic (IVD) devices, such as a pharmacogenetic assessment system or instrumentation for a clinical multiplex test system, what is the role of...
When budgeting for compliance into 2026 and beyond, how should an organization analyze the potential costs of engaging a GDPR Article 27 Representative? While specific fees vary, understanding the und...
When non-EU medical device manufacturers plan to enter the European market, they must appoint an EU Authorized Representative (AR) as mandated by the Medical Device Regulation (MDR). This AR serves as...
As non-EU importers prepare for the definitive phase of the Carbon Border Adjustment Mechanism (CBAM), a primary concern is understanding the financial implications of appointing a representative for ...
While it is not possible to state a specific dollar amount for FDA U.S. Agent services for 2026, as these are provided by private entities with market-driven fees, foreign medical device establishment...
As the Modernization of Cosmetics Regulation Act (MoCRA) establishes new requirements for foreign cosmetic facilities, many are asking about the cost of appointing a mandatory FDA U.S. Agent. While sp...
GDPR is not a scam. Scammers exploit it
For non-EU manufacturers of medical devices, selecting an EU Authorised Representative (AR) is a critical step for market access under the EU MDR. Beyond simply providing a European address, what are ...
With significant updates to EU cosmetic regulations anticipated, selecting a qualified EU Responsible Person (RP) has become a critical strategic decision for non-EU brands. Beyond simply fulfilling a...
For a medical device or Software as a Medical Device (SaMD) manufacturer planning its European compliance budget for 2026, what are the key service-level and risk-based factors that determine the scop...
Given the increased scrutiny by European authorities on data protection compliance for non-EU entities, how should a medical device or SaMD manufacturer without a physical establishment in the EU or U...
With the introduction of new EU regulations like the Carbon Border Adjustment Mechanism (CBAM), non-EU manufacturers and importers face the critical task of appointing an in-region representative. Bey...
When budgeting for compliance with the EU's Carbon Border Adjustment Mechanism (CBAM), non-EU importers often ask about the cost of appointing an Authorized Representative. However, a single fixed pri...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities that manufacture or process products for the U.S. market are required to designate a U.S. ...
When evaluating providers for a U.S. Agent under the Modernization of Cosmetics Regulation Act (MoCRA), what key factors and service levels typically influence the overall cost? The requirement for f...
When medical device manufacturers plan their compliance budgets for 2026, forecasting the cost of outsourced services like the Person Responsible for Regulatory Compliance (PRRC) is a critical task. G...
While establishing a precise budget for a Person Responsible for Regulatory Compliance (PRRC) service for 2026 is challenging without specific quotes, manufacturers can forecast costs by understanding...